As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.

Merck's Vaxneuvance – formerly known as V114 – is the first major competition to Pfizer's franchise in the big market for conjugate pneumococcal vaccines ... with its off-label use.

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

This year, pharmaceutical giant Merck (NYSE: MRK ... such as its pair of HPV vaccines, Gardasil and Gardasil 9. Further, the ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

Merck will face an important patent cliff by ... such as its pair of HPV vaccines, Gardasil and Gardasil 9. Further, the company has a deep pipeline, with more than 80 programs in phase 2 studies ...